Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
02/03/17
Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2017-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will participate in two upcoming investor conferences: Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday, February 7, 2017 in New York, NY 6th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 15, ... 
01/31/17
Seres Therapeutics Announces Key Findings from SER-109 Phase 2 Study Analyses
- Findings suggest that both misdiagnosis of C. difficile recurrent infection in some patients, and dosing that may have been suboptimal in certain patients, contributed to the previously reported SER-109 Phase 2 study outcome - - FDA discussions are ongoing regarding a new, redesigned clinical study for SER-109 - - Conference call at 8 a.m. ET today - CAMBRIDGE, Mass., January 31, 2017 —Seres Therapeutics Inc., (NASDAQ:MCRB), a leading mi... 
01/30/17
Seres Therapeutics to Host Conference Call and Webcast to Announce Key Findings from SER-109 Phase 2 Study Analyses
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2017-- Seres Therapeutics, Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Tuesday, January 31, 2017 at 8:00 a.m. ET to discuss the results of its in-depth analyses of the previously reported SER-109 Phase 2 clinical study in patients with multiply recurrent C. difficile infection. To ac... 
EventsMore
There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$9.09
0.00 (0.00%)
02/24/17 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.